All participants will initially undergo a run-in period on standardised medium-dose ICS/LABA to confirm persistent lack of ...

Companies remain exposed to heightened risks between the world’s largest markets and are cautious of the stability of ...

The US Department of Health and Human Services (HHS) said it is “taking immediate steps” to implement a recent Executive ...

Data presented at ATS 2025 showed that lung improvement in paediatric cystic fibrosis (CF) patients receiving ETI therapy is ...

Skye has entered a partnership with Arecor aimed at developing a higher formulation of the former’s obesity candidate, ...

The London Biotechnology Show returns for its highly anticipated second edition, building on the remarkable success of its ...

Novotech is a winner in the Diversity, Research and Development, and Marketing categories in the 2025 Pharmaceutical ...

The 5th Pharmaceutical Automation and Digitalisation Congress (AUTOMA+) will gather industry leaders in Vösendorf, Austria on ...

The agreement will see international initiatives to fight the next pandemic, but funding remains the weak link.

The Japanese MHLW has granted approval for the use of GSK’s Blenrep (belantamab mafodotin) combinations for MM.

An ATS 2025 session presented data showing that anti–IL-5 biologics significantly cut exacerbations in coexisting asthma and ...

The published long-term data suggests that the treatment could maintain its dominant position in the CF market.